Stock Analysis
Indoco Remedies Second Quarter 2025 Earnings: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024)
Indoco Remedies (NSE:INDOCO) Second Quarter 2025 Results
Key Financial Results
- Revenue: ₹4.34b (down 9.9% from 2Q 2024).
- Net loss: ₹95.7m (down by 127% from ₹350.8m profit in 2Q 2024).
- ₹1.09 loss per share (down from ₹3.82 profit in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Indoco Remedies Earnings Insights
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.
Performance of the Indian Pharmaceuticals industry.
The company's shares are down 11% from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with Indoco Remedies (including 2 which are potentially serious).
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:INDOCO
Indoco Remedies
Manufactures, markets, and sells formulations and active pharmaceutical ingredients in India and internationally.
